Type-specific Prevalence of Human Papillomavirus by Cervical Cytology among Women in Brasov, Romania

Moga, Marius; Irimie, Marius; Oanţă, A; Pascu, Alexandru; Burtea, Victoria

doi:10.7314/apjcp.2014.15.16.6887

Cited by 20 publications

(21 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In agreement with our results showing HPV positivity in 82.6% of H-SIL cases, a meta-analysis conducted using data from 423 studies revealed an overall HPV prevalence in 84% and 85% of H-SIL cases in Europe and globally, respectively [38]. The prevalence of HR-HPV genotypes has been reported to increase with the grade of cytological lesions in some [28, 31, 39] but not all published studies [20, 21, 40]. In the present work, such an association was not observed, probably due to the low number of HPV-positive L-SIL and H-SIL cases that were included for analysis.…”

Section: Discussionsupporting

confidence: 91%

HPV prevalence and type distribution in Cypriot women with cervical cytological abnormalities

2017

View full text Add to dashboard Cite

BackgroundHuman papillomavirus (HPV) is the most common sexually transmitted agent, and it can cause cervical lesions and cancer in females. Currently, information regarding the prevalence of HPV in Cyprus is lacking. The aim of this study was to evaluate the HPV type-specific prevalence in 596 women, aged 19–65 years, with cytological abnormalities. Additionally, in a subset of 348 women for whom cytology results of the Pap test were available, the association between HPV infection and cervical disease was investigated.MethodsHPV detection and typing was carried out using PCR and restriction fragment length polymorphism analysis, respectively.ResultsOverall, the HPV prevalence was 72.8%, and it was shown to be age dependent, with a decreasing prevalence until the age of 45 years (p = 0.0018, χ2). Two hundred and fifty-eight women (59.4%) were infected with high-risk HPV, 151 (34.8%) with low-risk HPV, and 25 (5.8%) with HPV types of unknown risk. The most common high-risk HPV type was HPV16 (17.7%), followed by HPV31 (12.9%), HPV58 (7.1%), HPV68 (4.6%), HPV18 (4.1%), and HPV56 (3.7%). Among the women for whom cytology results were available, 268 (77%) were HPV positive, with a sample distribution as follows: 188 (74%) had atypical squamous cells of undetermined significance (ASCUS), 61 (85.9%) had low-grade squamous intraepithelial lesion (L-SIL), and 19 (82.6%) had high-grade squamous intraepithelial lesion (H-SIL). HPV16 was the most common type among women affected by L-SIL (19.7%) and H-SIL (15.8%), with HPV31 being the most common type in women affected by ASCUS (16.5%).ConclusionsThe present study provides the first epidemiological data related to HPV prevalence and type distribution in Cypriot women with cytological abnormalities.

show abstract

Section: Discussionsupporting

confidence: 91%

HPV prevalence and type distribution in Cypriot women with cervical cytological abnormalities

2017

View full text Add to dashboard Cite

show abstract

“…MAU is appreciated in all trials to be as a marker of generalized endothelial dysfunction and atherosclerosis, data consistent with the findings of the present study as it was more frequently diagnosed in RH patients with atherosclerotic disease as ischemic heart disease and peripheral vascular disease [25][26][27][28][29][30]. The relationship between CV comorbidities and the presence of MAU was investigated in the i-SEARCH study on 21,867 patients with high-risk hypertension.…”

Section: Resultssupporting

confidence: 86%

Prevalence, Characteristics and Predictive Factors of Microalbuminuria in Resistant Systemic Arterial Hypertension

Gadau¹,

Ardeleanu²,

Folescu³

et al. 2018

Rev. Chim.

View full text Add to dashboard Cite

The present cross-sectional observational study was made in family medicine offices of Timi� County, Romania. The aim of the study was to investigate the prevalence of urinary microalbumin excretion (MAU) in resistant systemic arterial hypertension (RH), to analyze patients� biochemical and clinical characteristics, and the predictive factors for MAU. From a total number of 347 patients, MAU was detected in 76 cases (21.9%). The microalbuminuria positive patients were older, with significant higher office systolic blood pressure (BP) (155 � 13.50 vs 148 � 12.40 mmHg, p [ 0.0001) and diastolic blood pressure (94 � 12.20 vs 88 � 14.6 mmHg, p = 0.0013), higher prevalence of left ventricular hypertrophy, diabetes mellitus, obesity, ischemic and peripheral arterial disease. MAU positive patients presented statistical significant differences in biochemical data concerning: fasting plasma glucose (FPG) (118.80 � 32.02 vs 108.01 � 26.01 mg/dL, p = 0.003), impaired glucose tolerance (IGT) (10.52 % vs 4.94 %), glycated hemoglobin (HbA1c) (6.56 � 0.98% vs 5.96 � 0.91%, p [ 0.001), reduced estimated glomerular filtration rate (eGFR) (56.10 � 15.4 vs 69.30 � 17.5 ml/min/1.73m2, p [ 0.001) and higher potassium levels (4.71 � 0.43 vs 4.59 � 0.44 mg/dL, p = 0.0378). No significant differences were noticed regarding LDL- and HDL-cholesterol, triglycerides, uric acid and serum creatinine. In a logistic multivariate analysis independent predictors for MAU were: systolic BP (odds ratio, OR = 1.024, 95% confidence interval, CI:1.011-1.039, p [ 0.001), HbA1c (OR = 1.324, 95% CI: 1.078-1.724, p = 0.008) and eGFR (OR = 0.989, 95% CI: 0.977-0.999, p = 0.01). Our findings suggest that an important part of RH patients have microalbuminuria and highlight the importance of controlling its predictors, in order to improve patients� outcome.

show abstract

“…There are more than 200 types of HPVs described to date from which about 15 are designed as high-risk strains according to the propensity of malignant progression of virus-associated lesions (Di Domenico et al, 2012;Yuan CH, 2012;Hirchaud et al, 2013;Moga et al, 2014). The most prevalent high risk type is HPV16 that is responsible for the development of about 50-60% of all cervical cancers.…”

Section: Characteristic Features Of Cytotoxic Activity Of Flavonoids mentioning

confidence: 99%

Characteristic Features of Cytotoxic Activity of Flavonoids on Human Cervical Cancer Cells

Sak¹

2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Cervical cancer is the most common gynecologic malignancy worldwide and development of new therapeutic strategies and anticancer agents is an urgent priority. Plants have remained an important source in the search for novel cytotoxic compounds and several polyphenolic flavonoids possess antitumor properties. In this review article, data about potential anticarcinogenic activity of common natural flavonoids on various human cervical cancer cell lines are compiled and analyzed showing perspectives for the use of these secondary metabolites in the treatment of cervical carcinoma as well as in the development of novel chemotherapeutic drugs. Such anticancer effects of flavonoids seem to differentially depend on the cellular type and origin of cervical carcinoma creating possibilities for specific targeting in the future. Besides the cytotoxic activity per se, several flavonoids can also contribute to the increase in efficacy of conventional therapies rendering tumor cells more sensitive to standard chemotherapeutics and irradiation. Although the current knowledge is still rather scarce and further studies are certainly needed, it is clear that natural flavonoids may have a great potential to benefit cervical cancer patients.

show abstract

Type-specific Prevalence of Human Papillomavirus by Cervical Cytology among Women in Brasov, Romania

Cited by 20 publications

References 40 publications

HPV prevalence and type distribution in Cypriot women with cervical cytological abnormalities

HPV prevalence and type distribution in Cypriot women with cervical cytological abnormalities

Prevalence, Characteristics and Predictive Factors of Microalbuminuria in Resistant Systemic Arterial Hypertension

Characteristic Features of Cytotoxic Activity of Flavonoids on Human Cervical Cancer Cells

Contact Info

Product

Resources

About